Post-exercise Insulin Reductions in Type 1 Diabetes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01531855 |
Recruitment Status :
Completed
First Posted : February 13, 2012
Last Update Posted : August 4, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 1 Diabetes | Other: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 13 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | The Metabolic and Glycaemic Responses to Reductions in Rapid-acting Insulin Dose After Running Exercise in People With Type 1 Diabetes Mellitus. |
Study Start Date : | February 2012 |
Actual Primary Completion Date : | August 2012 |
Actual Study Completion Date : | August 2012 |

Arm | Intervention/treatment |
---|---|
Insulin dose
Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.
|
Other: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose
Dosage after exercise |
- 24 hour blood glucose area under the curve [ Time Frame: 24 hours ]24 hour, post-exercise, glucose area under the curve.
- Ketogenesis [ Time Frame: 60 minutes before and 24 hours post-exercise ]Blood beta-hydroxybutyrate concentrations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- T1DM,
- Male,
- basal-bolus regimen (insulin glargine / detemir with insulin lispro / aspart),
- HbA1c < 9.9%,
- aged 18-50.
Exclusion Criteria:
- HbA1c > 10%,
- not treated with basal-bolus (insulin glargine / detemir with insulin lispro / aspart),
- aged <18 > 50.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01531855
United Kingdom | |
Clinical Research Facility | |
Newcaslte upon Tyne, Tyne and Wear, United Kingdom, NE1 4LP |
Principal Investigator: | Daniel J West | Northumbria University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Northumbria University |
ClinicalTrials.gov Identifier: | NCT01531855 |
Other Study ID Numbers: |
west-walker1 |
First Posted: | February 13, 2012 Key Record Dates |
Last Update Posted: | August 4, 2014 |
Last Verified: | August 2014 |
T1DM, Exercise |
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases |
Immune System Diseases Insulin Insulin Lispro Insulin, Short-Acting Hypoglycemic Agents Physiological Effects of Drugs |